Artelo Biosciences, Inc. reported a net loss of approximately $12.9 million for the fiscal year ending December 31, 2025, an increase from a net loss of $9.8 million in the previous year. The company's total operating expenses rose to $11.4 million, up from $10.1 million in 2024, primarily due to increased professional fees related to financing activities and higher stock-based compensation costs. Research and development expenses decreased slightly to $5.4 million from $6.0 million, reflecting a reduction in research activities. The company has not generated any revenue to date and continues to rely on external financing to support its operations.
In terms of liquidity, Artelo reported cash and cash equivalents of $600,000 as of December 31, 2025, a significant decrease from $2.3 million at the end of 2024. Current liabilities increased to $4.0 million, compared to $1.8 million in the prior year, largely due to slower payments to vendors and the issuance of convertible notes. The company’s working capital deficit stood at $3.3 million, raising substantial doubt about its ability to continue as a going concern without additional financing.
Strategically, Artelo is advancing its clinical pipeline, which includes three key product candidates: ART27.13, ART26.12, and ART12.11. ART27.13, a dual cannabinoid agonist, is currently in a Phase 1b/2a trial for cancer-related anorexia, with interim results showing a mean weight gain of 6.38% in treated patients compared to a loss in the placebo group. ART26.12, a small molecule targeting chemotherapy-induced peripheral neuropathy, received FDA clearance for its IND application in July 2024 and has completed its Phase 1 clinical trial. ART12.11, a proprietary cocrystal composition of CBD, is in preclinical development with potential applications in anxiety disorders.
Looking ahead, Artelo plans to continue its focus on raising capital to fund its operations and clinical trials. The company has filed a shelf registration statement allowing it to sell up to $75 million in securities and has engaged in various financing activities, including the issuance of convertible notes and common stock. However, the company acknowledges the challenges it faces in securing additional funding and the potential impact of market conditions on its ability to raise capital. The management remains committed to advancing its product candidates while navigating the financial uncertainties inherent in the biopharmaceutical industry.
About ARTELO BIOSCIENCES, INC.
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company based in California, focused on developing therapeutics that modulate lipid-signaling pathways, particularly the endocannabinoid system. Its key products include ART27.13 for cancer-related anorexia and ART26.12 for chemotherapy-induced peripheral neuropathy. With significant market opportunities exceeding $2 billion for cancer anorexia and over $1 billion for neuropathy, Artelo is advancing innovative therapies through clinical trials and strategic partnerships.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.